1. Sai Life Sciences Ltd IPO Overview
Sai Life Sciences Ltd IPO open for subscription on December 11, 2024, and will close on December 13, 2024. The final allotment of shares will be confirmed on Monday December 16, 2024. The share’s to be listed Exchange on Wednesday December 18, 2024, and listing Exchange on BSE NSE.
Sai Life Sciences Ltd IPO price band has been set between ₹522 to ₹549 per equity share and Lot Size 27 share’s per lot.
The total issue size of Sai Life Sciences Ltd IPO is approximately ₹3042.62 Cr. This comprises 55,421,123 equity shares offered to the public.
As of December 10, the Gray Market Premium (GMP) for the Sai Life Sciences Ltd IPO stands at ₹31, reflecting market sentiment. This premium signals robust demand, underscoring the positive sentiment surrounding the IPO.
2. Sai Life Sciences Ltd IPO Timeline
Sai Life Sciences Ltd IPO is expected to open soon, with the following key dates:
- IPO Opening Date -: “The IPO is set to open on Wednesday, December 11, 2024.”
- IPO Closing Date -: “The IPO will close on Friday, December 13, 2024.”
- Finalization of Allotment -: The IPO allotment status will be declared on Monday, December 16, 2024.
- Initiation of Refunds -: The refund amount will be credited to your bank account on Tuesday, December 17, 2024.
- Credit of Shares to Demat Account -: The shares will be credited to your Demat account on Tuesday, December 17, 2024.
- Listing Date -: The IPO will be listed on the stock exchanges on Wednesday, December 18, 2024, on NSE, BSE.
3. IPO Size (IPO Price, Lot Size, and Issue Size)
- Price Band -: Sai Life Sciences IPO price band has been set between ₹522 to ₹549 per share.
- Lot Size -: The IPO lot size has been set at 27 shares per lot.
- Issue Size -: The IPO Issue size is estimated to be around ₹3042.62 Cr.
- Fresh Issue -: The IPO fresh issue size is ₹950.00 crore.
- Minimum Order Quantity -: Retail Investors can apply for a minimum of 1 lot.
- Maximum Order Quantity -: Retail Investors can apply for a maximum of 13 lots.
The lot size and price band will be crucial for retail investors looking to participate. Keep a close eye on these details once the IPO opens for subscription.
4. About Sai Life Sciences Ltd
Sai Life Sciences Limited, incorporated in 1999, is a contract research, development, and manufacturing organization (CRDMO) specializing in small-molecule new chemical entities (NCEs). It serves over 280 clients globally, including top pharmaceutical companies across the US, UK, Europe, and Japan. Its services cover integrated discovery, chemistry, biology, and drug development, as well as large-scale manufacturing capabilities. The company employs more than 3,100 professionals, with a significant portion dedicated to scientific research.
Sai Life Sciences has a robust track record in the pharmaceutical services industry but faces challenges such as dependency on clients’ success and regulatory compliance risks. Despite this, its broad service portfolio and strategic partnerships position it as a leader in the CRDMO space
6. Sai Life Sciences Ltd Company Financial Information
Below is a snapshot of the company’s financial performance, highlighting key financial metrics over the past few years:
Financial Indicator | FY 2024 | FY 2023 | FY 2022 |
Revenue | ₹1,494.27 Cr | ₹1,245.11 Cr | ₹897.74 Cr |
Profit/Loss After Tax | ₹ 82.81 Cr | ₹ 9.99 Cr | ₹ 6.23 Cr |
Total Assets | ₹ 2,275.14 Cr | ₹ 2,186.65 Cr | ₹ 2,164.23 Cr |
Net Worth | ₹ 974.34 Cr | ₹ 887.29 Cr | ₹ 877.76 Cr |
Reserves | ₹ 953.99 Cr | ₹ 867.43 Cr | ₹ 859.17 Cr |
Borrowings | ₹ 710.16 Cr | ₹ 699.23 Cr | ₹ 751.32 Cr |
Amount in ₹ Cr. |